To view or add a comment, sign in Breakthrough Designation for Liver Disease TherapyThe landscape of metabolic health shifted significantly as the US FDA granted Breakthrough Therapy Designation to efimosfermin, a once-monthly investigational liver therapy targeting Metabolic Dysfunction-Associated Steatohepatitis (MASH) (My, 2026)
Despite the pleiotropic properties of GLP-1, including its insulinotropic effect found in rats, pigs, and humans, its extremely short plasma half-life of less than 2 minutes constituted a huge brick wall in the path of GLP-1 to be developed as a glucose-lowering medication
Beyond the scale, the same participants saw improvements in blood pressure, cholesterol markers, blood sugar control, and liver fat
I sometimes get a craving for something salty and crunchy
We believe that client trust is priority and our team works on giving them 100% pure Authentic products
55 Morote-GarciaJ